Consort Medical gets US thumbs up
Consort Medical said the first product to use its built-in dose counter had been given the go-ahead by the US Food and Drug Administration.
Consort Medical said the first product to use its built-in dose counter had been given the go-ahead by the US Food and Drug Administration.
Consort's Integrated Dose Counter (IDC) is being used in Teva's QNASL nasal aerosol, which treats of nasal seasonal allergy symptoms.
The firm had been developing its IDC for several years in response to a patient and compliance need to let patients know if their device contained sufficient drug and to indicate when they need to seek a further prescription.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
It provides patients with an indication of how many doses are left inside the canister in line with FDA guidance.
"We are very pleased to announce that the FDA has approved the use of our IDC with Teva's QNASL, making this our first commercially marketed integrated dose counter," said chief executive Jon Glenn.
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
What happens if you can’t pay your tax bill, and what is "Time to Pay"?
Millions are due to file their tax return this Friday as the self-assessment deadline closes. Though the nightmare is not over until you pay the taxman what you owe - or face a penalty. But what happens if you can't afford to pay HMRC your tax bill, and what is "Time to Pay"?
By Kalpana Fitzpatrick Published
-
What does Rachel Reeves’s plan for growth mean for UK investors?
Rachel Reeves says she is going “further and faster” to kickstart the UK economy, but investors are unlikely to be persuaded
By Katie Williams Published